Oppenheimer Maintains Outperform on Relay Therapeutics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $25 to $24.

August 07, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on Relay Therapeutics but lowers the price target from $25 to $24.
The Outperform rating suggests a positive outlook, but the slight reduction in the price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100